Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Non-cash Items (2018 - 2025)

Cue Biopharma's Non-cash Items history spans 8 years, with the latest figure at $7.2 million for Q3 2025.

  • For Q3 2025, Non-cash Items rose 37.94% year-over-year to $7.2 million; the TTM value through Sep 2025 reached $7.2 million, up 37.94%, while the annual FY2024 figure was $5.1 million, 11.97% up from the prior year.
  • Non-cash Items for Q3 2025 was $7.2 million at Cue Biopharma, up from $6.3 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $7.2 million in Q3 2025 and bottomed at $3.1 million in Q1 2021.
  • The 5-year median for Non-cash Items is $4.4 million (2022), against an average of $4.6 million.
  • The largest annual shift saw Non-cash Items increased 0.18% in 2023 before it skyrocketed 37.94% in 2025.
  • A 5-year view of Non-cash Items shows it stood at $3.6 million in 2021, then grew by 23.57% to $4.4 million in 2022, then grew by 4.53% to $4.6 million in 2023, then increased by 11.97% to $5.1 million in 2024, then skyrocketed by 40.44% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Non-cash Items are $7.2 million (Q3 2025), $6.3 million (Q2 2025), and $6.0 million (Q1 2025).